All analyses
AI analysis

Asiri Surgical Hospital PLC: research report

Fairly valuedbullishOct 7, 2026

Evidence points bullish: profit grew faster than revenue while debt and interest pressure fell, and the shares trade at their cheapest P/B on record. The catch is weak cash conversion, at 0.33 times operating profit.

Reports without a focus are public, one per stock per day. Generation usually takes about 15 minutes, and we'll notify you when it's ready.

Why bullish

  • June-quarter net profit grew 11.6% year-on-year, ahead of 7.4% revenue growth, as net margin widened.
  • Annual debt against owners' equity fell to 24.2%, while interest cover improved to 4.78 times.
  • The shares trade on 6.3 times trailing earnings and 0.72 times book value, both below healthcare-sector medians.

Against this. Operating cash flow was only 0.33 times operating profit in the latest annual period, so much of the reported operating profit had not converted into cash.

Operating margin
18.1%
latest quarter
Net margin
15.4%sector 13.0%
from 12.1% a year earlier, revenue +17.6%
Return on equity
12.0%
twelve months to Sep 30, 2026, unaudited
P/E
7.0sector 11.8
earnings Rs 1.84 per share, year to Sep 2026
P/B
0.83sector 1.36
book Rs 15.34 per share
Dividend yield
0.00%sector 0.00%
trailing twelve months

Current figures, updated daily from filings to Sep 30, 2026. The report below was written on Oct 7, 2026. Sector figures are the median of 6 listed companies in the same sector.

Overview

Asiri Surgical Hospital operates a specialist private hospital offering surgical, diagnostic and post-operative care. The latest filed quarter showed profit growing faster than revenue as the net margin edged higher, while the preceding annual accounts showed a much lower debt burden and improved ability to meet finance costs.

Price performance

At LKR 10.10 on 7 October 2026, the share had fallen 27.9% over one month, against a 4.8% decline in the ASPI. It closed at its 52-week low, so the valuation is being assessed after a severe retreat rather than near a recent peak.

The record shows four falls of 15% or more in three years, the deepest 63% and not yet recovered. A LKR 1 million order is about 58% of what trades on a typical day, a large part of a day's trading; median daily turnover was LKR 1.7 million, which limits how quickly a meaningful position can be built or exited. Sixty-day volatility was below its own one-year norm, while recent volume ran above its 60-day norm.

Valuation

At 6.3 rupees for every rupee of trailing profit, the P/E is below the healthcare-sector median. The P/B of 0.72 means the market price is 72 cents for each rupee of net assets, also below the sector median; the trailing return on equity was 11.5%, so the discount to book is not explained by a loss-making business.

The company scores 64 of 100 on price against book value, earnings and dividends, placing it in the moderately undervalued band. Its P/B is “the cheapest day in the record since February 2012”, while its P/E is “cheaper than 95% of days since February 2012”. A buyer at this price is relying on a trailing earnings base for which the latest quarter contributed 23.2%, with that quarter's margin only modestly ahead of a year earlier.

There is no current dividend yield and no dividend is on record in the last two years. The latest recorded payout was LKR 0.30 per share for FY2025, so the valuation rests on earnings and asset value rather than income.

News and sentiment

Direct coverage is thin: the 90-day record contains two material articles, both negative. The only supplied item, reported on 17 August 2026, concerned Softlogic Holdings and noted that a tax dispute involving Asiri Surgical Hospital was under appeal; it does not provide terms or a quantified effect on AMSL's earnings.

There are no confirmed or pending corporate actions in the supplied record, and no dividend is on record in the last two years.

Financials

In the June 2026 quarter, revenue rose 7.4% year-on-year to LKR 2.0 billion and net profit rose 11.6% to LKR 226 million. Profit therefore grew faster than the hospital's top line, increasing the earnings attributable to the shares, although the latest quarter was not exceptional on its own June history.

Gross margin was 43.2% versus 43.2% a year earlier, operating margin is unavailable in the latest filing versus 17.3% a year earlier, and net margin was 11.1% versus 10.7%. The gross margin was among its best June readings, ranking 2 of 6 comparable June quarters; net margin ranked 4 of 6, a middling result for that quarter.

For the twelve months to June 2026, revenue grew 6.6% and net margin was 12.6%. The latest audited year to March 2026 had already delivered a 151.6% increase in net profit, but 13.4% of that year's group profit belonged to minority shareholders rather than AMSL ordinary shareholders.

Risks

The leading financial risk is cash generation. In the year to March 2026, operating cash flow was only 0.33 times operating profit and free cash flow was negative LKR 95 million, meaning reported operating profit was not fully arriving as cash after investment spending.

Gearing, meaning debt against owners' equity, was 24.2%, lower than the prior year, and interest cover, meaning operating profit divided by the interest bill, improved to 4.78 times. The current ratio was 1.09, meaning it had LKR 1.09 of short-term assets, including receivables and supplies, for each LKR 1.00 of bills due within a year; this is adequate but leaves limited room if collections weaken.

Healthcare-sector news also highlights greater state involvement in hospital provision and cyber-security exposure. These are sector conditions rather than company-specific events, and the supplied data does not quantify their effect on AMSL.

Outlook

As at 7 October 2026, the next material event is the September 2026 interim-quarter filing, expected between 6 and 14 November. It will show whether the June-quarter combination of revenue growth, stable gross margin and higher net profit continued, and will supersede the figures used in this analysis.

The available data cannot quantify the outcome of the tax appeal mentioned in August reporting, nor does it establish any earnings effect from wider healthcare policy developments. The next filing is therefore the nearer evidence on the operating business, while the appeal remains an unquantified uncertainty.

About this report. Generated on Oct 7, 2026 from market data up to Oct 7, 2026, 2 material news articles over 90 days and financials to Jun 30, 2026, and scored 64 of 100 on value (moderately undervalued) when it was written. Every figure is drawn from EquityLK's own data on this company. AI research can contain errors, so treat it as a starting point, not investment advice.

Previous reports